Defects in the striatal neuropeptide Y system in X-linked dystonia-parkinsonism.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Brain : a journal of neurology

• Publication date

  2013-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/brain/awt084PMID 23599389
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multifaces of neuropeptide Y in the brain--neuroprotection, neurogenesis and neuroinflammation.

  2012cited by this paper
• Cell type-specific localization of optineurin in the striatal neurons of mice: implications for neuronal vulnerability in Huntington's disease.

  2012cited by this paper
• IDH Mutation Detection in Formalin‐Fixed Paraffin‐Embedded Gliomas Using Multiplex PCR and Single‐Base Extension

  2012cited by this paper
• Neuropeptide Y and its role in CNS disease and repair.

  2012cited by this paper
• Mutations in GNAL cause primary torsion dystonia

  2012cited by this paper
• Sustained expression of a neuron-specific isoform of the Taf1 gene in development stages and aging in mice.

  2012cited by this paper
• Neuropeptide transmission in brain circuits.

  2012cited by this paper
• NPY promotes chemokinesis and neurogenesis in the rat subventricular zone

  2011cited by this paper
• Basal Ganglia Disorders Associated with Imbalances in the Striatal Striosome and Matrix Compartments

  2011cited by this paper
• Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation

  2011cited by this paper
• L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission

  2011cited by this paper
• Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.

  2010cited by this paper
• Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures.

  2010cited by this paper
• Heterogeneity and Diversity of Striatal GABAergic Interneurons

  2010cited by this paper
• Neuropeptide Y

  2009cited by this paper
• Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice.

  2009influential reference
• The monogenic primary dystonias.

  2009cited by this paper
• Striosome-matrix pathology and motor deficits in the YAC128 mouse model of Huntington's disease.

  2008cited by this paper
• Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia

  2008cited by this paper
• Neuropeptide Y Promotes Neurogenesis in Murine Subventricular Zone

  2008cited by this paper
• Habits, rituals, and the evaluative brain.

  2008cited by this paper
• In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease

  2008cited by this paper
• Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy.

  2008cited by this paper
• Roles of μ-Opioid Receptors in GABAergic Synaptic Transmission in the Striosome and Matrix Compartments of the Striatum

  2008cited by this paper
• Peptidergic influences on proliferation, migration, and placement of neural progenitors in the adult mouse forebrain

  2008cited by this paper
• The effect of neurodegenerative diseases on the subventricular zone

  2007cited by this paper
• Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism.

  2007cited by this paper
• Compartmental loss of striatal medium spiny neurons in multiple system atrophy of parkinsonian type

  2007cited by this paper
• Evidence for stroke-induced neurogenesis in the human brain

  2006cited by this paper
• Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide.

  2006cited by this paper
• The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington's disease human brain.

  2005cited by this paper
• Functional anatomy of the basal ganglia in X‐linked recessive dystonia‐parkinsonism

  2005cited by this paper
• Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain

  2003cited by this paper
• Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism

  2003cited by this paper
• Rat forebrain neurogenesis and striatal neuron replacement after focal stroke

  2002cited by this paper
• The natural history of sex-linked recessive dystonia parkinsonism of Panay, Philippines (XDP).

  2002cited by this paper
• Neuronal replacement from endogenous precursors in the adult brain after stroke

  2002cited by this paper
• TAFII250: a transcription toolbox

  2001cited by this paper
• TAF(II)250: a transcription toolbox.

  2001cited by this paper
• Mutant huntingtin enhances excitotoxic cell death.

  2001cited by this paper
• Neuropeptide Y functions as a neuroproliferative factor

  2001cited by this paper
• Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis.

  2000cited by this paper
• Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum.

  2000cited by this paper
• Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease

  1998cited by this paper
• Neurochemical architecture of the human striatum

  1997cited by this paper
• Early Loss of Neostriatal Striosome Neurons in Huntington's Disease

  1995cited by this paper
• Neuropathology of lubag (x‐linked dystonia parkinsonism)

  1993cited by this paper
• Spatial distributions of chemically identified intrinsic neurons in relation to patch and matrix compartments of rat neostriatum

  1993cited by this paper
• Relative loss of the striatal striosome compartment, defined by calbindin-D28k immunostaining, following developmental hypoxic-ischemic injury.

  1993cited by this paper
• Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity‐akinesia

  1990cited by this paper
• Met‐enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration

  1990cited by this paper
• Neurotransmitters and neuromodulators in the basal ganglia.

  1990cited by this paper
• Somatostatin and neuropeptide Y concentrations in pathologically graded cases of huntington's disease

  1988cited by this paper
• Differential loss of striatal projection neurons in Huntington disease.

  1988cited by this paper
• Neuropeptide Y-immunoreactive neurons in the striatum of cat and monkey: morphological characteristics, intrinsic organization and co-localization with somatostatin.

  1986cited by this paper
• Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system--II. Immunohistochemical analysis.

  1986cited by this paper
• Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.

  1985cited by this paper
• Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide

  1982cited by this paper
• Torsion dystonia in Panay, Philippines.

  1976influential reference

• Myelin pathology is a key feature of X-linked Dystonia Parkinsonism

  2025cites this paper
• MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism

  2025cites this paper
• Gut Neuropeptide Involvement in Parkinson's Disease.

  2025cites this paper
• Neuropeptide Y at the crossroads of neurodegeneration: Mechanistic insights and emerging therapeutic strategies.

  2025cites this paper
• MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism

  2025cites this paper
• A cross-species spatial transcriptomic atlas of the human and non-human primate basal ganglia

  2025cites this paper
• Functional pathology of neuroleptic-induced dystonia based on the striatal striosome-matrix dopamine system in humans

  2024cites this paper
• The roles of TAF1 in neuroscience and beyond

  2024cites this paper
• Neurological disorders caused by novel non-coding repeat expansions: clinical features and differential diagnosis.

  2024cites this paper
• Advancements in the Study of Clinical Features and Molecular Functions in Heterogeneous TAF1-associated Clinical Phenotypes

  2024cites this paper
• Dystonia and Parkinson's disease: Do they have a shared biology?

  2023cites this paper
• A Network Imaging Biomarker of X‐Linked Dystonia‐Parkinsonism

  2023cites this paper
• A structural magnetic resonance imaging review of clinical motor outcomes from deep brain stimulation in movement disorders

  2023cites this paper
• Proteomic analysis of X-linked dystonia parkinsonism disease striatal neurons reveals altered RNA metabolism and splicing

  2023cites this paper
• Cross talk about the role of Neuropeptide Y in CNS disorders and diseases.

  2023cites this paper
• Endemic parkinsonism: clusters, biology and clinical features

  2023cites this paper
• Specificity of striatal dopamine D1 system in humans: implications for clinical use of D1 receptor-agonists in Parkinson's disease

  2023cites this paper
• Morphology and morphometry of interneuron subpopulations of the marmoset monkey (Callithrix jacchus) striatum.

  2023cites this paper
• In Vivo Brain Sodium Disequilibrium in ATP1A3‐Related Rapid‐Onset Dystonia‐Parkinsonism

  2022cites this paper
• X-linked dystonia parkinsonism: epidemiology, genetics, clinical features, diagnosis, and treatment

  2022cites this paper
• Tissue-specific and repeat length-dependent somatic instability of the X-linked dystonia parkinsonism-associated CCCTCT repeat

  2022cites this paper
• A dual dopaminergic therapy with L-3,4-dihydroxyphenylalanine and chlorpromazine for the treatment of blepharospasm, a focal dystonia: Possible implications for striosomal D1 signaling

  2022cites this paper
• Prodromal X‐Linked Dystonia‐Parkinsonism is Characterized by a Subclinical Motor Phenotype

  2022cites this paper
• Cerebellar and Midbrain Lysosomal Enzyme Deficiency in Isolated Dystonia

  2022cites this paper
• Demystifying the Neuroprotective Role of Neuropeptides in Parkinson’s Disease: A Newfangled and Eloquent Therapeutic Perspective

  2022cites this paper
• Tissue-specific and repeat length-dependent somatic instability of the X-linked dystonia parkinsonism-associated CCCTCT repeat

  2022cites this paper
• Variation in TAF1 Expression in Female Carrier-Induced Pluripotent Stem Cells and Human Brain Ontogeny Has Implications for Adult Neostriatum Vulnerability in X-Linked Dystonia Parkinsonism

  2022cites this paper
• Neuropeptides: Roles and Activities as Metal Chelators in Neurodegenerative Diseases

  2021cites this paper
• X‐Linked Parkinsonism: Phenotypic and Genetic Heterogeneity

  2021cites this paper
• The Emerging Role of Neuropeptides in Parkinson’s Disease

  2021cites this paper
• Promise and challenges of dystonia brain banking: establishing a human tissue repository for studies of X-Linked Dystonia-Parkinsonism

  2021cites this paper
• X‐Linked Dystonia‐Parkinsonism (“Lubag”) May Present with Peripheral Synucleinopathy

  2021cites this paper
• Neuroimaging and neuropathology studies of X-linked dystonia parkinsonism.

  2020influential citation
• The investigation of the T-type calcium channel enhancer SAK3 in an animal model of TAF1 intellectual disability syndrome.

  2020cites this paper
• TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X‐linked Dystonia‐Parkinsonism

  2020cites this paper
• Combined dystonias: clinical and genetic updates

  2020cites this paper
• Lysosomal enzyme deficiency and GBA mutations in Dystonia

  2020cites this paper
• Spatiotemporal Up-Regulation of Mu Opioid Receptor 1 in Striatum of Mouse Model of Huntington’s Disease Differentially Affecting Caudal and Striosomal Regions

  2020cites this paper
• Parallel Emergence of a Compartmentalized Striatum with the Phylogenetic Development of the Cerebral Cortex

  2019cites this paper
• Neuronal-specific microexon splicing of TAF1 mRNA is directly regulated by SRRM4/nSR100

  2019cites this paper
• Association of Pallidal Neurostimulation and Outcome Predictors With X-linked Dystonia Parkinsonism

  2019cites this paper
• Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases

  2019cites this paper
• Neuropathology of Dystonia

  2019cites this paper
• X-Linked Dystonia-Parkinsonism: recent advances.

  2019cites this paper
• Altered glutamate response and calcium dynamics in iPSC‐derived striatal neurons from XDP patients

  2018cites this paper
• Basal ganglia and cerebellar pathology in X-linked dystonia-parkinsonism

  2018cites this paper
• MOLECULAR BASIS OF PATHOGENESIS OF DYSTONIA AMONG INDIAN PATIENTS

  2018cites this paper
• A review of psychiatric co‐morbidity described in genetic and immune mediated movement disorders

  2017cites this paper
• Dopamine-Induced Changes in Gαolf Protein Levels in Striatonigral and Striatopallidal Medium Spiny Neurons Underlie the Genesis of l-DOPA-Induced Dyskinesia in Parkinsonian Mice

  2017cites this paper
• Increased insula-putamen connectivity in X-linked dystonia-parkinsonism☆

  2017cites this paper
• Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1

  2017cites this paper
• Clinicopathological Phenotype and Genetics of X-Linked Dystonia–Parkinsonism (XDP; DYT3; Lubag)

  2017influential citation
• The Striosome and Matrix Compartments of the Striatum: A Path through the Labyrinth from Neurochemistry toward Function.

  2017cites this paper
• X-linked Dystonia-Parkinsonism patient cells exhibit altered signaling via nuclear factor-kappa B.

  2017cites this paper
• Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity

  2017cites this paper
• Neuroanatomical changes extend beyond striatal atrophy in X-linked dystonia parkinsonism.

  2016cites this paper
• Decreased N-TAF1 expression in X-linked dystonia-parkinsonism patient-specific neural stem cells

  2016influential citation
• Putaminal Mosaic Visualized by Tyrosine Hydroxylase Immunohistochemistry in the Human Neostriatum

  2016cites this paper
• Immunohistochemical mapping of neuropeptide Y in the tree shrew brain

  2015cites this paper
• Non-motor symptoms in genetically defined dystonia: Homogenous groups require systematic assessment.

  2015cites this paper
• Development of a highly sensitive immunohistochemical method to detect neurochemical molecules in formalin-fixed and paraffin-embedded tissues from autopsied human brains

  2015cites this paper
• Substance P Weights Striatal Dopamine Transmission Differently within the Striosome-Matrix Axis

  2015cites this paper
• Postsynaptic Density Protein 95 in the Striosome and Matrix Compartments of the Human Neostriatum

  2015cites this paper
• Abnormal High-Frequency Burst Firing of Cerebellar Neurons in Rapid-Onset Dystonia-Parkinsonism

  2014cites this paper
• Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2

  2014cites this paper
• A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease

  2014cites this paper
• Peptide therapeutics in neurodegenerative disorders.

  2014cites this paper
• A pathophysiological link between dystonia, striatal interneurons and neuropeptide Y.

  2013cites this paper
• Neurological disorders caused by novel non-coding repeat expansions: clinico-genetic features and roadmap to diagnosis

  year unknowncites this paper